Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The advent of novel therapeutics that specifically target signaling pathways activated by genetic alterations has revolutionized the way patients with lung cancer are treated. Although only few and largely ineffective chemotherapeutic regimens were available 10 years ago, a lung tumor diagnosed today requires extensive pathologic subtyping and diagnosis of genome alterations to afford more effective treatment (eg, in EGFR-mutant adenocarcinoma). This change of paradigm has several profound implications, ranging from preclinical work on the mechanism of action to a novel, more biologically oriented taxonomy and from genome diagnostics to trial design. Here, we have summarized these developments into six conceptual paradigms that illustrate the transition from empirical cancer medicine to mechanistically based individualized oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Research works printed but not linked: 60
- 10.1056/NEJMoa011954 · DOI · Paper page
- 10.1056/NEJMoa1006448 · DOI · Paper page
- 10.1038/nm.1890 · DOI · Paper page
- 10.1073/pnas.0907325106 · DOI · Paper page
- 10.1101/gr.133645.111 · DOI · Paper page
- 10.1126/scitranslmed.3001451 · DOI · Paper page
- 10.1371/journal.pone.0020351 · DOI · Paper page
- 10.1158/2159-8274.CD-11-0005 · DOI · Paper page
- 10.1056/NEJMoa040938 · DOI · Paper page
- 10.1126/science.1099314 · DOI · Paper page
- 10.1038/nature04873 · DOI · Paper page
- 10.1016/j.cell.2011.09.016 · DOI
- 10.1056/NEJMoa044238 · DOI · Paper page
- 10.1002/cbic.201000352 · DOI · Paper page
- 10.1016/j.bmc.2008.02.053 · DOI · Paper page
- 10.1073/pnas.0502860102 · DOI · Paper page
- 10.1158/0008-5472.CAN-11-3720 · DOI
- Regales L, 2009, J Clin Invest, 119, 3000
- 10.1200/jco.2011.29.15_suppl.7525 · DOI · Paper page
- Rodenhuis S, 1988, Cancer Res, 48, 5738
- 10.1038/nature08460 · DOI · Paper page
- 10.1016/j.cell.2009.03.017 · DOI · Paper page
- 10.1016/j.cell.2012.02.059 · DOI · Paper page
- 10.1200/jco.2011.29.15_suppl.3004 · DOI · Paper page
- 10.1101/gad.1815309 · DOI · Paper page
- 10.1038/nature04304 · DOI · Paper page
- 10.1172/JCI37127 · DOI · Paper page
- 10.1056/NEJMc053610 · DOI · Paper page
- 10.1126/scitranslmed.3002356 · DOI · Paper page
- 10.1073/pnas.89.7.2965 · DOI · Paper page
- Yap TA, J Clin Oncol
- 10.1200/JCO.2012.43.1825 · DOI
- Walter AO, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
- 10.1073/pnas.0409773102 · DOI · Paper page
- 10.1073/pnas.0905056106 · DOI · Paper page
- 10.1172/JCI28656 · DOI · Paper page
- 10.1158/0008-5472.CAN-10-2956 · DOI · Paper page
- 10.1158/1078-0432.CCR-11-1648 · DOI · Paper page
- 10.1126/scitranslmed.3003967 · DOI · Paper page
- 10.1097/JTO.0b013e318206a221 · DOI · Paper page
- 10.1200/JCO.2007.13.0062 · DOI · Paper page
- 10.1097/PAS.0b013e31815cb162 · DOI · Paper page
- 10.1038/nrg2841 · DOI · Paper page
- 10.1073/pnas.74.12.5463 · DOI · Paper page
- 10.1038/nm1437 · DOI · Paper page
- 10.1371/journal.pone.0019601 · DOI · Paper page
- 10.1038/ng1975 · DOI · Paper page
- 10.1093/nar/17.7.2503 · DOI · Paper page
- 10.1093/nar/gkq579 · DOI
- 10.1158/2159-8290.CD-11-0184 · DOI · Paper page
- 10.1038/ng.2396 · DOI · Paper page
- 10.1093/jnci/djs141 · DOI · Paper page
- Shaw AT, 2012, J Clin Oncol, 30, 482s, 10.1200/JCO.2011.37.2516 · DOI · Paper page
- 10.1111/j.0006-341X.2004.00193.x · DOI
- 10.1038/nbt1068 · DOI · Paper page
- 10.1371/journal.pone.0003908 · DOI
- 10.2967/jnumed.109.065367 · DOI
- 10.1200/JCO.2010.32.4939 · DOI · Paper page
- 10.1200/jco.2011.29.18_suppl.cra7506 · DOI · Paper page
- 10.1200/jco.2012.30.18_suppl.cra10529 · doi:10.1200/jco.2012.30.18_suppl.cra10529
Cited by
Radiomics: the bridge between medical imaging and personalized medicine
Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.141 · Cited by 5,688
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Precision oncology: an overview
Garraway, L. A., Verweij, J., & Ballman, K. V. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4799 · Cited by 405
Genetics and biomarkers in personalisation of lung cancer treatment
Rosell, R., Bivona, T. G., & Karachaliou, N. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61715-8 · Cited by 305
CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer
Rizzo, S., Petrella, F., Buscarino, V., De Maria, F., Raimondi, S., Barberis, M., Fumagalli, C., Spitaleri, G., Rampinelli, C., De Marinis, F., et al. (2016) · European Radiology · doi:10.1007/s00330-015-3814-0 · Cited by 270
Scheffler, M., Bos, M., Gardizi, M., König, K., Michels, S., Fassunke, J., Heydt, C., Künstlinger, H., Ihle, M., Ueckeroth, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2834 · Cited by 147
“Thus, to date the identification and clinical evaluation of further targetable oncogenes is a major goal in lung cancer research [6, 7].”
BackgroundSelf-citation
Metadata
- Authors
- Buettner, R., Wolf, J., & Thomas, R. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-05-20
- Volume
- 31
- Issue
- 15
- Pages
- 1858-1865
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138490951
- Cited by
- 121
- References
- 30
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.